Legacy Financial Advisors Inc. Acquires 1,340 Shares of Elevance Health, Inc. $ELV

Legacy Financial Advisors Inc. raised its holdings in shares of Elevance Health, Inc. (NYSE:ELV) by 54.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,816 shares of the company’s stock after purchasing an additional 1,340 shares during the quarter. Legacy Financial Advisors Inc.’s holdings in Elevance Health were worth $1,338,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also bought and sold shares of the business. Vanguard Group Inc. lifted its position in Elevance Health by 0.6% during the third quarter. Vanguard Group Inc. now owns 22,998,645 shares of the company’s stock valued at $7,431,322,000 after purchasing an additional 141,747 shares during the last quarter. Wellington Management Group LLP lifted its position in Elevance Health by 4.8% during the third quarter. Wellington Management Group LLP now owns 6,621,297 shares of the company’s stock valued at $2,139,473,000 after purchasing an additional 303,099 shares during the last quarter. Artisan Partners Limited Partnership lifted its position in Elevance Health by 24.5% during the third quarter. Artisan Partners Limited Partnership now owns 4,576,805 shares of the company’s stock valued at $1,478,857,000 after purchasing an additional 901,626 shares during the last quarter. First Eagle Investment Management LLC lifted its position in Elevance Health by 0.6% during the fourth quarter. First Eagle Investment Management LLC now owns 4,022,874 shares of the company’s stock valued at $1,410,219,000 after purchasing an additional 24,271 shares during the last quarter. Finally, Invesco Ltd. lifted its position in Elevance Health by 22.9% during the third quarter. Invesco Ltd. now owns 2,597,488 shares of the company’s stock valued at $839,300,000 after purchasing an additional 484,303 shares during the last quarter. Institutional investors own 89.24% of the company’s stock.

Wall Street Analyst Weigh In

ELV has been the topic of several recent research reports. Evercore increased their price target on Elevance Health from $345.00 to $360.00 in a report on Thursday, April 23rd. Citigroup raised shares of Elevance Health to a “buy” rating in a research note on Wednesday, April 29th. Wells Fargo & Company dropped their price objective on shares of Elevance Health from $424.00 to $391.00 and set an “overweight” rating for the company in a research note on Friday, January 30th. Mizuho lowered their target price on shares of Elevance Health from $413.00 to $350.00 and set an “outperform” rating for the company in a report on Wednesday, March 11th. Finally, Bank of America upgraded shares of Elevance Health from a “neutral” rating to a “buy” rating and raised their target price for the stock from $405.00 to $435.00 in a report on Wednesday, April 29th. Thirteen equities research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $384.58.

Elevance Health Price Performance

Elevance Health stock opened at $393.12 on Wednesday. The firm has a 50-day moving average price of $316.48 and a 200-day moving average price of $332.85. The firm has a market capitalization of $85.37 billion, a PE ratio of 16.72, a price-to-earnings-growth ratio of 2.17 and a beta of 0.66. The company has a current ratio of 1.48, a quick ratio of 1.48 and a debt-to-equity ratio of 0.70. Elevance Health, Inc. has a 12-month low of $273.71 and a 12-month high of $412.96.

Elevance Health (NYSE:ELV) last released its earnings results on Wednesday, April 22nd. The company reported $12.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $10.74 by $1.84. The firm had revenue of $49.49 billion during the quarter, compared to analyst estimates of $48.21 billion. Elevance Health had a net margin of 2.62% and a return on equity of 15.58%. The business’s revenue was up 1.5% on a year-over-year basis. During the same quarter last year, the business earned $11.97 EPS. Elevance Health has set its FY 2026 guidance at 19.850- EPS. As a group, equities research analysts forecast that Elevance Health, Inc. will post 26.79 EPS for the current year.

Elevance Health Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, June 25th. Stockholders of record on Wednesday, June 10th will be issued a $1.72 dividend. This represents a $6.88 annualized dividend and a dividend yield of 1.8%. The ex-dividend date is Wednesday, June 10th. Elevance Health’s dividend payout ratio (DPR) is 29.26%.

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.